

Hernan Trimarchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5708172/publications.pdf>

Version: 2024-02-01

60
papers

1,903
citations

516710

16
h-index

276875

41
g-index

65
all docs

65
docs citations

65
times ranked

2145
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. <i>Kidney International</i> , 2017, 91, 1014-1021.	5.2	748
2	A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 691-701.	6.1	228
3	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	5.2	198
4	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
5	Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. <i>Journal of Nephrology</i> , 2016, 29, 791-797.	2.0	46
6	Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1280-1285.	0.7	44
7	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.8	37
8	Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 581-586.	0.7	28
9	Podocyturia: What is in a name?. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 51-56.	2.5	26
10	Podocyturia: Potential applications and current limitations. <i>World Journal of Nephrology</i> , 2017, 6, 221.	2.0	24
11	Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 739-741.	2.9	22
12	H1N1 infection and the kidney in critically ill patients. <i>Journal of Nephrology</i> , 2010, 23, 725-31.	2.0	22
13	External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort. <i>Kidney International Reports</i> , 2020, 5, 1753-1763.	0.8	21
14	Creatinine- vs. cystatin C-based equations compared with 99mTcDTPA scintigraphy to assess glomerular filtration rate in chronic kidney disease. <i>Journal of Nephrology</i> , 2012, 25, 1003-1015.	2.0	21
15	Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. <i>World Journal of Nephrology</i> , 2013, 2, 103-10.	2.0	20
16	Cytomegalovirus maculopapular eruption in a kidney transplant patient. <i>Transplant Infectious Disease</i> , 2001, 3, 47-50.	1.7	18
17	Randomized Trial of Methylcobalamin and Folate Effects on Homocysteine in Hemodialysis Patients. <i>Nephron</i> , 2002, 91, 58-63.	1.8	18
18	IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description. <i>Kidney International</i> , 2019, 95, 750-756.	5.2	17

#	ARTICLE	IF	CITATIONS
19	Clopidogrel Diminishes Hemodialysis Access Graft Thrombosis. <i>Nephron Clinical Practice</i> , 2006, 102, c128-c132.	2.3	16
20	Biomarcadores en la lesión renal aguda: ¿ paradigma o evidencia?. <i>Nefrología</i> , 2016, 36, 339-346.	0.4	15
21	Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 53-60.	2.9	15
22	Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 324-329.	2.5	15
23	Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2012, 5, 1.	1.8	14
24	Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 459-463.	2.0	13
25	Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?. <i>Pediatric Nephrology</i> , 2018, 33, 2095-2101.	1.7	13
26	Elevated Pro-Brain Natriuretic Peptide, Troponin T and Malnutrition Inflammatory Score in Chronic Hemodialysis Patients with Overt Cardiovascular Disease. <i>Nephron Clinical Practice</i> , 2011, 117, c198-c205.	2.3	12
27	Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2015, 9, 2-14.	0.6	12
28	In hemodialysis, adiponectin, and pro-brain natriuretic peptide levels may be subjected to variations in body mass index. <i>Hemodialysis International</i> , 2011, 15, 477-484.	0.9	11
29	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 913-925.	2.9	11
30	Role of aliskiren in blood pressure control and renoprotection. <i>International Journal of Nephrology and Renovascular Disease</i> , 2011, 4, 41.	1.8	10
31	In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia. <i>Nephron Extra</i> , 2017, 7, 52-61.	1.1	10
32	Pro-calcitonin and inflammation in chronic hemodialysis. <i>Medicina</i> , 2013, 73, 411-6.	0.6	10
33	Downregulation of megalin, cubilin, CIC-5 and podocin in Fabry nephropathy: potential implications in the decreased effectiveness of enzyme replacement therapy. <i>Journal of Nephrology</i> , 2020, 34, 1307-1314.	2.0	9
34	COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment?. <i>Journal of Nephrology</i> , 2020, 33, 1119-1120.	2.0	9
35	Crescents and IgA Nephropathy: A Delicate Marriage. <i>Journal of Clinical Medicine</i> , 2022, 11, 3569.	2.4	9
36	Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. <i>International Journal of Nephrology</i> , 2017, 2017, 1-7.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Late-Onset Cytomegalovirus-Associated Interstitial Nephritis in a Kidney Transplant. <i>Nephron</i> , 2002, 92, 490-494.	1.8	7
38	Lyso-Gb3 Increases α 5 β 1 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3659.	2.4	7
39	Crescents in primary glomerulonephritis: a pattern of injury with dissimilar actors. A pathophysiologic perspective. <i>Pediatric Nephrology</i> , 2022, 37, 1205-1214.	1.7	7
40	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
41	H1N1 infection and acute kidney injury in the critically ill. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 506-506.	2.9	6
42	Proteinuria, 99mTc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease. <i>ISRN Nephrology</i> , 2014, 2014, 1-16.	1.2	6
43	Belatacept and mediastinal histoplasmosis in a kidney transplant patient. <i>Journal of Nephropathology</i> , 2016, 5, 84-87.	0.2	6
44	Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 771-777.	2.9	6
45	The Kidney in Fabry Disease. <i>FIRE Forum for International Research in Education</i> , 2016, 4, 232640981664816.	0.7	5
46	In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride?. <i>Case Reports in Nephrology</i> , 2017, 2017, 1-4.	0.4	5
47	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	4.5	4
48	Aliskiren and the Kidney: Beyond Hypertension. <i>Nephrology Research & Reviews</i> , 2009, 1, 1-4.	0.2	3
49	Proteinuria and its relation to diverse biomarkers and body mass index in chronic hemodialysis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2013, 6, 113.	1.8	3
50	The implications of focal segmental glomerulosclerosis in children with IgA nephropathy. <i>Pediatric Nephrology</i> , 2020, 35, 2043-2047.	1.7	3
51	Focal Segmental Glomerulosclerosis and Scheduled Pretransplant Plasmapheresis: A Timely Diagnosis of Nail-Patella Syndrome Avoided More Futile Immunosuppression. <i>Case Reports in Nephrology</i> , 2020, 2020, 1-4.	0.4	3
52	SARS-CoV-2 and Fabry nephropathy: potential risks and the pathophysiological perspective. <i>Journal of Nephropathology</i> , 2020, 9, e36-e36.	0.2	2
53	Proteinuria: A Cross Road Where the Complement and the Plasminogen-plasmin Systems Meet. <i>Journal of Integrative Nephrology and Andrology</i> , 2016, 3, 37.	0.3	2
54	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?. <i>International Journal of Nephrology</i> , 2012, 2012, 1-6.	1.3	1
56	Mucin-1 Gene Mutation and the Kidney: The Link between Autosomal Dominant Tubulointerstitial Kidney Disease and Focal and Segmental Glomerulosclerosis. <i>Case Reports in Nephrology</i> , 2018, 2018, 1-5.	0.4	1
57	Residual urinary output in high body mass index individuals on chronic hemodialysis: A disregarded life vest?. <i>World Journal of Nephrology</i> , 2014, 3, 317.	2.0	1
58	FP194IN FABRY NEPHROPATHY, INCREASED URINARY PODOCYTE uPAR-PODOCALYXIN COLOCALIZATION IS DECREASED AND MAY BE INVOLVED IN PODOCYTE DETACHMENT AND START AT EARLY STAGES OF THE DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
59	The C677T thermolabile variant of methylene tetrahydrofolate reductase on homocysteine, folate and vitamin B12 in a hemodialysis center. <i>Medicina</i> , 2002, 62, 149-53.	0.6	0
60	Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy. <i>Medicina</i> , 2007, 67, 445-50.	0.6	0